Recent research published in Frontiers in Nutrition has found no causal link between vitamin D deficiency and the development of myasthenia gravis (MG). This contradicts earlier studies suggesting that lower vitamin D levels might contribute to the risk of MG. The study utilized Mendelian randomization to analyze data from two genome-wide association studies (GWAS).
Read More
The investigators concluded that circulating vitamin D levels do not causally affect the risk of developing MG, reporting an odds ratio (OR) of 0.91 with a p-value of 0.532. Previous studies noted that patients with MG typically have lower vitamin D levels compared to the general population, fueling speculation that vitamin D deficiency could be a risk factor.
Myasthenia gravis is an autoimmune neuromuscular disease that results in weakness of skeletal muscles, primarily due to antibodies that block communication between nerves and muscles. It is estimated that up to 250 million people worldwide are affected by MG.
The team analyzed data from the UK Biobank and the Sunshine consortium, which included over 495,000 participants of European ancestry and a meta-analysis that encompassed 79,366 patients specifically with MG. Using various methods to assess genetic variation related to vitamin D, they found no evidence that serum vitamin D levels causally increase the risk of MG. The OR in their primary analysis was 0.90, with a 95% confidence interval (CI) of 0.67 to 1.22 and a p-value of 0.532.
While some studies have linked vitamin D supplementation to improvements in symptoms such as fatigue, the new findings indicate that the relationship is not causal. The authors acknowledged limitations in their study, including a cohort predominantly comprised of AchR-positive patients and the lack of data on other antibody types. They emphasized the need for larger studies that include diverse cohorts to further clarify these findings.